These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 24324749)

  • 1. Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis.
    Cao W; Zhao C; Shen C; Wang Y
    PLoS One; 2013; 8(12):e82092. PubMed ID: 24324749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis--a comparison with routine biochemical markers.
    Chan WK; Sthaneshwar P; Nik Mustapha NR; Mahadeva S
    PLoS One; 2014; 9(9):e105903. PubMed ID: 25184298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
    Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease.
    Kim YS; Jung ES; Hur W; Bae SH; Choi JY; Song MJ; Kim CW; Jo SH; Lee CD; Lee YS; Choi SW; Yang JM; Jang JW; Kim SG; Jung SW; Kim HK; Chae HB; Yoon SK
    Clin Mol Hepatol; 2013 Jun; 19(2):120-30. PubMed ID: 23837136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Value of serum osteoprotegerin in noninvasive diagnosis of nonalcoholic steatohepatitis].
    Yang M; Liu Y; Zhou G; Guo X; Zou S; Liu S; Jiang L; Liu Y; Zhu L; Guo C; Zhao J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):96-101. PubMed ID: 26983475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.
    Cusi K; Chang Z; Harrison S; Lomonaco R; Bril F; Orsak B; Ortiz-Lopez C; Hecht J; Feldstein AE; Webb A; Louden C; Goros M; Tio F
    J Hepatol; 2014 Jan; 60(1):167-74. PubMed ID: 23973932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.
    Feldstein AE; Wieckowska A; Lopez AR; Liu YC; Zein NN; McCullough AJ
    Hepatology; 2009 Oct; 50(4):1072-8. PubMed ID: 19585618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels.
    Tsutsui M; Tanaka N; Kawakubo M; Sheena Y; Horiuchi A; Komatsu M; Nagaya T; Joshita S; Umemura T; Ichijo T; Matsumoto A; Yoshizawa K; Aoyama T; Tanaka E; Sano K
    J Clin Gastroenterol; 2010 Jul; 44(6):440-7. PubMed ID: 20104187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apoptotic and anti-apoptotic seromarkers for assessment of disease severity of non-alcoholic steatohepatitis.
    El Bassat H; Ziada DH; Hasby EA; Nagy H; Abo Ryia MH
    Arab J Gastroenterol; 2014 Mar; 15(1):6-11. PubMed ID: 24630506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein A, combined with alanine aminotransferase and aspartate aminotransferase, contributes to predicting the occurrence of NASH: a cross-sectional study.
    Zhang Y; He H; Zeng YP; Yang LD; Jia D; An ZM; Jia WG
    Lipids Health Dis; 2020 Jun; 19(1):134. PubMed ID: 32527258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 13. A new detection system for serum fragmented cytokeratin 18 as a biomarker reflecting histologic activities of human nonalcoholic steatohepatitis.
    Eguchi A; Iwasa M; Yamada M; Tamai Y; Shigefuku R; Hasegawa H; Hirokawa Y; Hayashi A; Okuno K; Matsushita Y; Nakatsuka T; Enooku K; Sakaguchi K; Kobayashi Y; Yamaguchi T; Watanabe M; Takei Y; Nakagawa H
    Hepatol Commun; 2022 Aug; 6(8):1987-1999. PubMed ID: 35485207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index.
    Polyzos SA; Kountouras J; Papatheodorou A; Katsiki E; Patsiaoura K; Zafeiriadou E; Papadopoulou E; Zavos C; Terpos E
    Ann Hepatol; 2013; 12(5):749-57. PubMed ID: 24067262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Composite Blood Biomarker Including AKR1B10 and Cytokeratin 18 for Progressive Types of Nonalcoholic Fatty Liver Disease.
    Choi SJ; Yoon S; Kim KK; Kim D; Lee HE; Kim KG; Shin SK; Park IB; Kim SM; Lee DH
    Diabetes Metab J; 2024 Jul; 48(4):740-751. PubMed ID: 38311058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study.
    Wu XX; Zheng KI; Boursier J; Chan WK; Yilmaz Y; Romero-Gómez M; El Kassas M; Targher G; Byrne CD; Huang ZM; Zheng MH
    EClinicalMedicine; 2021 Nov; 41():101145. PubMed ID: 34646997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma cathepsin D levels: a novel tool to predict pediatric hepatic inflammation.
    Walenbergh SM; Houben T; Hendrikx T; Jeurissen ML; van Gorp PJ; Vreugdenhil AC; Adriaanse MP; Buurman WA; Hofker MH; Mosca A; Lindsey PJ; Alisi A; Liccardo D; Panera N; Koek GH; Nobili V; Shiri-Sverdlov R
    Am J Gastroenterol; 2015 Mar; 110(3):462-70. PubMed ID: 25732418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical and histological features of non-alcoholic fatty liver disease].
    Shi JP; Xun YH; Hu CB; Zhang L; Liu H; Lou GQ; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):812-6. PubMed ID: 19958638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of Cytokeratin-18M65 in Diagnosing Non-Alcoholic Steatohepatitis in Japanese Population.
    Hasegawa Y; Kim SR; Hatae T; Ohta M; Fujinami A; Sugimoto K; Kim KI; Imoto S; Tohyama M; Kim SK; Ikura Y; Kudo M
    Dig Dis; 2015 Oct; 33(6):715-20. PubMed ID: 26488474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease.
    Sorbi D; Boynton J; Lindor KD
    Am J Gastroenterol; 1999 Apr; 94(4):1018-22. PubMed ID: 10201476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.